Domain Therapeutics and Chime Biologics Ink Cancer Immunotherapy Agreement

Domain Therapeutics and Chime Biologics signed a manufacturing service agreement for the production of Domain’s best-in-class Treg depleting anti-CCR8 antibody candidate, DT-7012. This phase of manufacturing aims to deliver an effective therapeutic for cancer patients worldwide, according to officials at both companies.

Chime Biologics will ensure stable cell line development (CLD) and DT-7012 candidate manufacturing to support clinical trials in strategic countries. Chime Biologics’ first global modular facility with single-use bioprocessing technology meets international cGMP standards with proven audit track records, notes Jimmy Wei, PhD, president, Chime Biologics.

DT-7012 is an anti-CCR8 mAb depleting tumor-infiltrating Tregs, major immunosuppressive cells. Treg depletion with anti-CCR8 mAb has demonstrated an anti-tumor potency as a monotherapy. DT-7012 has a proven best-in-class potential compared to other clinical-stage CCR8 antibodies, paving the way for effective GPCR-targeting immunotherapies, aiming to activate anti-tumor immunity for cancer patients unresponsive to other treatments, continues Wei. Phase I clinical studies of DT-7012 are expected to start in early 2025 for solid tumors and mid-2025 for cutaneous T-cell lymphoma (CTCL).

“We look forward to progressing this strategic partnership, which combines Domain’s leading anti-CCR8 antibody candidate with Chime Biologics’ CLD to commercial manufacturing expertise, contributing to the development of DT-7012 for various cancers,” says Wei.

“We’re thrilled to collaborate with Chime Biologics, a great scientific and manufacturing expert, to advance DT-7012, our leading anti-CCR8 candidate, to the next development stage,” adds Stephan Schann, PhD, CSO, Domain Therapeutics. “This new GPCR-targeting immunotherapy has immense potential to unlock the immune system’s cancer fighting abilities and help patients globally. At Domain, we prioritize precision research and innovation and embrace new partnerships with organizations that share our vision and passion to advance immuno-oncology.”

Previous articleProteomics in Portland: A Video Update from the U.S. HUPO Conference
Next articleCAR T Cells Target Two Proteins, Shrink Brain Tumors in Phase I Trial